Hasan Jalaeikhoo
Overview
Explore the profile of Hasan Jalaeikhoo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
106
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tayanloo-Beik A, Eslami A, Sarvari M, Jalaeikhoo H, Rajaeinejad M, Nikandish M, et al.
Oncol Rev
. 2024 Aug;
18:1411736.
PMID: 39091989
The global incidence of cancer is increasing, with estimates suggesting that there will be 26 million new cases and 17 million deaths per year by 2030. Cancer stem cells (CSCs)...
2.
Mohsenizadeh S, Rajaeinejad M, Khoshfetrat M, Arefizadeh R, Mousavi S, Mosaed R, et al.
Adv Exp Med Biol
. 2024 Jun;
1474():179-199.
PMID: 38842787
Recent advancements in personalized treatments, such as anthracycline chemotherapy, coupled with timely diagnoses, have contributed to a decrease in cancer-specific mortality rates and an improvement in cancer prognosis. Anthracyclines, a...
3.
Arjmand B, Alavi-Moghadam S, Faraji Z, Aghajanpoor-Pasha M, Jalaeikhoo H, Rajaeinejad M, et al.
Adv Exp Med Biol
. 2024 May;
1470:115-128.
PMID: 38811486
Colorectal cancer is a global health concern with high incidence and mortality rates. Conventional treatments like surgery, chemotherapy, and radiation therapy have limitations in improving patient survival rates. Recent research...
4.
Ahmadvand M, Shokrollahi Barough M, Barkhordar M, Faridfar A, Ghaderi A, Jalaeikhoo H, et al.
BMC Cancer
. 2023 Nov;
23(1):1090.
PMID: 37950209
Introduction: A new type of immune cell transplantation called allogeneic NK cell infusion is proposed as a potential universal off-the-shelf cell product for adoptive immune cell therapy in hematologic malignancies....
5.
Alahyari S, Rajaeinejad M, Jalaeikhoo H, Chegini L, Almasi Aghdam M, Asgari A, et al.
PLoS One
. 2022 Aug;
17(8):e0268712.
PMID: 35930526
Purpose: Available but insufficient evidence shows that changes may occur in the immune system following coronavirus disease 2019 (COVID-19). The present study aimed at evaluating immunological changes in patients with...
6.
Alahyari S, Moradi M, Rajaeinejad M, Jalaeikhoo H
Expert Rev Hematol
. 2022 May;
15(6):539-546.
PMID: 35584541
Introduction: COVID-19 crisis continues around the world. Some patients developed complications after the disease, which have been reported in limited studies. The aim of this study is to comprehensively assess...
7.
Alahyari S, Rajaeinejad M, Jalaeikhoo H, Amani D
Arch Iran Med
. 2022 Apr;
25(2):127-132.
PMID: 35429952
Background: Severe cases of coronavirus disease 2019 (COVID-19) often experience hyper-inflammatory reactions, acute respiratory distress syndrome (ARDS), blood clotting, and organ damage. The most prominent immunopathology of advanced COVID-19 is...
8.
Mohammadi F, Rostami G, Assad D, Shafiei M, Hamid M, Jalaeikhoo H
Lab Med
. 2021 Jun;
52(6):584-596.
PMID: 34128532
Objective: To determine whether polymorphisms of SLC22A1 and SLCO1B3 genes could predict imatinib (IM) response and chronic myeloid leukemia (CML) risk. Methods: We genotyped SLC22A1 (c.480G > C, c.1222A > ...
9.
Chaleshi V, Aghdaei H, Nourian M, Iravani S, Jalaeikhoo H, Rajaeinejad M, et al.
Gastroenterol Hepatol Bed Bench
. 2021 May;
14(2):108-114.
PMID: 33968337
Aim: The aim of this study was to evaluate the expression of and the relationship between its expression with clinical characteristics in an Iranian gastric cancer patient. Background: Long non-coding...
10.